Registry of Li Fraumeni and Li Fraumeni Like Syndromes
Condition(s) studied
Study summary
ReLF is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been developed to corroborate and integrate data from different resources and aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.
Eligibility
Primary outcome measure(s)
- Natural History and Epidemiology — Since the disease is rare, the timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
Assessment of epidemiological information. Anthropometric data: weight in kg, height in cm. In addition, weight and height will be combined to report BMI as kg/m\^2 Clinical details of the tumor: site of the lesion, number of recurrence(s), presence/absence of metastasis, size of lesion in cm\^3 Additional clinical data: type of surgery, age at surgery in years are updated at each follow up and retrospectively (when possible). Clinical reports, medical charts and imaging are the primary source of data.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Irccs Istituto Ortopedico Rizzoli | Bologna | Emilia-Romagna | Recruiting |
| IRCCS Istituto Ortopedico Rizzoli | Bologna | Emilia-Romagna | Enrolling By Invitation |
More Istituto Ortopedico Rizzoli trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04982744 on ClinicalTrials.gov ↗ ← All trials in Italy